Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.

doi:10.1016/j.jcyt.2020.07.011

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.

Cytotherapy - 1 Dec 2020

Gannon Philippe O, Harari Alexandre, Auger Aymeric, Murgues Clément, Zangiacomi Vincent, Rubin Olivier, Ellefsen Lavoie Kim, Guillemot Laurent, Navarro Rodrigo Blanca, Nguyen-Ngoc Tu, Rusakiewicz Sylvie, Rossier Laetitia, Boudousquié Caroline, Baumgaertner Petra, Zimmermann Stefan, Trueb Lionel, Iancu Emanuela M, Sempoux Christine, Demartines Nicolas, Coukos George, Kandalaft Lana E

Abstract excerpt

BACKGROUND AIMS: Several studies report on Good Manufacturing Process (GMP)-compliant manufacturing protocols for the ex vivo expansion of tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory melanoma and other solid malignancies. Further opportunities for improvements in terms of ergonomy and operating time have been identified. METHODS: To enable GMP-compliant TILs production for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Automation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Count

Share to Cell Culture Techniques

Share to Cryopreservation

Share to Hospitals

Share to Kinetics

Share to Lymphocytes, Tumor-Infiltrating

Share to Quality Control

Source

Open in PubMed

Identifiers

PMID: 33069566
DOI: 10.1016/j.jcyt.2020.07.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.PMID 33069566Read ↗

Towards a commercial process for the manufacture of genetically modified T cells for therapySemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialSemantic proximity Read ↗

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read ↗

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read ↗

Reproducible and Efficient Phenotyping for Cell Therapy Manufacturing Using the Accellix Automated Flow Cytometer Platform.Semantic proximity Read ↗

Towards automated manufacturing of clinical scale gene-modified T cellsSemantic proximity Read ↗

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forwardSemantic proximity Read ↗

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy.Semantic proximity Read ↗

Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.Semantic proximity Read ↗

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaSemantic proximity Read ↗

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.